The Voice features host Gloria Burns in a meaningful conversation with Roxie Soto from the Leukemia & Lymphoma Society (LLS) to highlight the organization’s mission, patient support programs, ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Mixed phenotype acute leukemia has qualities of both lymphoid and myeloid leukemias. These mixed qualities make it very difficult to diagnose and treat. The outlook for people with this type of ...

We often think of blood as the uniform red liquid encountered after a kitchen accident or at the doctor’s office. While this is true, on a microscopic level blood is made up of highly heterogeneous ...